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Risk Stratification in Autoimmune Cholestatic Liver
Diseases: Opportunities for Clinicians and Trialists
Palak J. Trivedi,1 Christophe Corpechot,2 Albert Pares,3 and Gideon M. Hirschfield1
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent
autoimmune cholestatic liver diseases, that disproportionate to their incidence and prev-
alence, remain very important causes of morbidity and mortality for patients with liver
disease. Mechanistic insights spanning genetic risks and biological pathways to liver
injury and fibrosis have led to a renewed interest in developing therapies beyond urso-
deoxycholic acid that are aimed at both slowing disease course and improving quality of
life. International cohort studies have facilitated a much greater understanding of dis-
ease heterogeneity, and in so doing highlight the opportunity to provide patients with a
more individualized assessment of their risk of progressive liver disease, based on clini-
cal, laboratory, or imaging findings. This has led to a new approach to patient care that
focuses on risk stratification (both high and low risk); and furthermore allows such
stratification tools to help identify patient subgroups at greatest potential benefit from
inclusion in clinical trials. In this article, we review the applicability and validity of risk
stratification in autoimmune cholestatic liver disease, highlighting strengths and weak-
nesses of current and emergent approaches. (HEPATOLOGY 2015; 00:000–000)
P
rimary biliary cirrhosis (PBC) and primary scleros-
ing cholangitis (PSC) are chronic autoimmune
cholestatic liver diseases, for which clinical outcome
is largely dictated by development of cirrhosis, portal
hypertension (PH), and variable predisposition to malig-
nancy.1-4 Rates of clinical progression vary, and accurately
identifying disease course is of critical importance to
patients, clinicians, as well as those committed to develop-
ing new, effective and affordable treatments.5 Patients
seek reassurance and guidance as to their own prognosis,
and clinicians wish to confidently recognize those at high-
est risk of poor outcomes as equally as they strive to reas-
sure individuals with good prognosis. Partnerships with
industry are essential to drug development; and collec-
tively all those involved in clinical trial design, recruit-
ment and analysis wish to understand unmet need and
conduct studies of new therapies as carefully constructed
interventions that deliver Specific, Measurable, Achieva-
ble, Relevant and Time-cost limited outputs. Such ven-
tures seek to “de-risk” drug development pathways where
possible, but maximize opportunity to advance therapy
for patient benefit in a timely way.
Herein, we present an appraisal of existing parameters
that stratify individuals with PBC and PSC, before
examining the effectiveness and applicability of more
incipient classification systems (Fig. 1). The strengths
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and weaknesses of various approaches are highlighted
specifically throughout, as well more generally with
regard to study design (Table 1).
Clinical History and Phenotypes
The full appreciation of the breadth of PBC as a dis-
ease has evolved as awareness has risen, particularly given
widespread access to anti-mitochondrial antibody (AMA)
testing, reactivity of which in the presence of cholestasis
facilitates robust and timely patient identification without
need for histological confirmation.6,7 PBC is increasingly
identified at an earlier precirrhotic stage,8 and well-
conducted multicenter cohort studies have aided in the
recognition of variant presentations (Table 2), including
male patients and women age <50 years.9 Ursodeoxy-
cholic acid (UDCA) is the only approved therapy, with
diminished disease progression evident in treated patients
and significantly improved 10-year transplant-free sur-
vival (78% vs. 66%; P < 0.001).3,8,10-12 Pooled survival
indices nevertheless remain lower than age- and sex-
matched control populations.10-12
Modeling the clinical course of PSC, in contrast to
PBC, is far more testing, perhaps inevitably so given a
lower incidence and absence of a defined serological
marker. This is paralleled by a clinical phenotype driven
by variable, unpredictable consequences related to
chronic inflammation, fibrosis and neoplasia of medium-
to large-sized bile ducts. In the largest population-based
study to date (n 5 590), disease was validated as being
male predominant (60%), with a median age at diag-
nosis of 40 years.13 However, PSC can develop at any
age, with younger patients frequently manifesting a hepa-
titic presentation.14 Associations with inflammatory
bowel disease (IBD) are well recognized and 70% of
PSC patients have a history of colitis, which confers a 5-
fold greater risk of colonic cancer relative to IBD alone,
as well as increased susceptibility to cholangiocarcinoma
(CCA) independent of liver disease stage. PSC portends
a standardized mortality ratio (SMR) more than 4-fold
that of a matched control population, although there is
discrepancy between event-free survival (EFS) times
across transplant centers versus true population-based
cohorts (median, 13.2 vs. 21.3 years; P < 0.00113).
Population-level data thus highlight significant challenges
to prognostic modeling and unmask the inadequate phe-
notypic representation of early-stage disease and inherent
selection bias with tertiary-center-restricted reporting.
Symptom Complex
Pruritus and fatigue are frequent symptoms associated
with cholestasis15 and approximately 60% of patients
with PBC are asymptomatic at diagnosis, with as few as
5% remaining symptom free over time.16 The prognos-
tic importance of fatigue in PBC is contentious, but
concern is perhaps best highlighted in the prospective
cohort study from Jones et al. (n 5 136),12 wherein
transplant-free survival (TFS) was significantly shorter
among fatigued patients relative to nonfatigued, disease-
matched controls (56% vs. 74%; P < 0.0001), inde-
pendent of UDCA provision. Although a consensus bio-
logical explanation for fatigue is lacking, presenting age
and sex heavily influence the clinical phenotype, with
young women (a group failing UDCA therapy more
commonly) having the greatest symptom burden.9,17
However, there is no evidence that symptomatic presen-
tations impart additional discriminatory value to exist-
ing risk-prediction models.
Symptomatic presentations in PSC similarly vary
(36%-56%), with over 20% developing symptoms de
novo during follow-up.18-20 Relapsing-remitting episodes
of acute cholangitis are a frequent concern; and data from
several cohorts suggest symptomatic presentations carry
poorer TFS and malignancy-free survival.18,20 One third
of CCA are diagnosed within the first year of PSC pre-
sentation (annual incidence thereafter: 0.5%-1.5%; life-
time risk: 7%-15%),13,18 and patients often report
abdominal pain preceding diagnosis, particularly those
with a prolonged history of IBD (>1 year).18,21
Biochemical Response Criteria in PBC
Serum bilirubin is well established as a predictor of
outcome and incorporated into several prognostic scor-
ing systems.22,23 However, “time-constrained” models,
such as the Mayo score, which include bilirubin together
with other markers of cirrhosis, are limited to prediction
of short-term survival (<2 years) in relatively late-stage
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disease. A potentially more applicable surrogate is serum
alkaline phosphatase (ALP); and in the largest ever
meta-analysis of individual patient data (n 5 4,845), a
near log-linear relationship was illustrated between ALP
and subsequent risk of transplantation/death across sev-
eral time points.8 This study demonstrated that ALP
bestows prognostic information early in the clinical
course, incremental to the predictive power of bilirubin
and independent of follow-up time, presenting age, sex,
disease stage, and treatment status.
To this effect, several studies illustrate strong associa-
tions between percentage reduction or absolute decreases/
normalization in serum ALP (in isolation or combination
with other biochemical covariates) and significantly
improved clinical outcome.10,11,24,25 Indeed, the majority
who successfully attain predefined biochemical thresholds
1-2 years after UDCA treatment (13-15 mg/kg/day)
experience survival patterns akin to that of an age- and
sex-matched control population (Table 3A). All response
criteria have been independently and externally validated,
with Paris I capturing the greatest breadth of biochemical
changes. Furthermore, there is clear, negative prognostic
impact of biochemical nonresponse on future hepatocel-
lular carcinoma (HCC) risk in PBC patients, independ-
ently and additive to the effects posed by male sex and
advanced baseline disease stage.2
Although a small proportion of PBC patients with
early-stage disease meet response criteria free of ther-
apy,26 this represents an understudied population, and
presently, it is not possible to identify individuals likely
to endure a good prognosis regardless of intervention.
Inversely, paradigms reliant on waiting 1 year for thera-
peutic evaluation may leave high-risk patients (future
nonresponders) on a medical treatment lacking benefit
and reduce impact of second-line therapy because of
delayed initiation. In this regard, a prospective study
Table 1. Common Pitfalls in Risk Stratification Studies
Precedents Apprehensions
Well recognized; frequently addressed
Inadequate follow-up time  Restricts assessment to late-stage events
 Poorly predictive of at-risk groups from disease outset
Single-center studies  Lack of independent, external validation
 May not be generalizable
Small sample size  Inadequate statistical power
 Increased type 1 error
Well recognized; infrequently addressed
Representation limited to retrospective
data collection
 Incomplete data
 Selection bias and confounding factors
 Reduces statistical power
Extrapolation of risk stratifiers beyond
original intended endpoint/time point
 Increased type 2 error
Tertiary-center-restricted studies  Recruitment/referral bias; not necessarily
representative of the disease globally
Logistic regression (odds ratios; ORs) applied
for clinical endpoints that are not time-constrained
 Time-variable events (e.g., death, transplantation) necessitate
Cox regression (hazard ratios; HRs), or equivalent
“Time-dependent” covariates modeled as “time-constant”  Inadequate representation of chronal displacement between
potential risk factors and the measured endpoint
Poorly recognized; infrequently addressed
Predictive utility of a continuous variable
not proven prior to applying to dichotomization
 Subjugation of variability
 Increased type 1 error
 Conceals nonlinearity between covariates and clinical outcomes
Independently predictive covariates deemed additive  Incorrect classification of risk through weaker stratifiers
Incorrect estimation of median EFS times  Incorrect approach:
- Calculated median: midpoint of all patients’ follow-up times
 Correct approach:
- Actuarial median: time at which 50% of the cohort meets the
clinical endpoint according to Kaplan-Meier estimates
Contrary inferences  Favorable clinical outcomes suggested for low-risk groups stratified according to
dichotomous variables, despite EFS dwarfing that of a matched control population
4 TRIVEDI ET AL. HEPATOLOGY, Month 2015
from China suggests that attainment rates, as well as
predictive value, is identical when biochemical response
is assessed at 6 versus 12 months (Table 3B),27 but this
needs validation.
Demographic Variations
Population-level and international multicenter studies
have substantiated the predictive performance of bio-
chemical response criteria, independently of disease
stage and UDCA exposure.9,28 Perhaps most notable is
the UK-PBC study (n 5 2,353), which not only recog-
nized an increasing prevalence of younger presenting
women (25% age <50), but also an inverse correlation
of patient age and likelihood of meeting biochemical
response.9 Attainment rates were reportedly 50% in
women age below 40 and echo results of an earlier,
Table 2. Variant Presentations
A. PBC
Phenotypic Variant (% of Patient Population) Prognostic Implication
Male sex 2,9,32
(5%-10%)
 Older age at diagnosis relative to women (60 vs. 55 years; P < 0.001)
 Greater frequency of nonresponse (63% vs. 76%; P < 0.001)
- Likely attributable to more advanced baseline disease
 Increased HCC risk in biochemical nonresponders, as well as patients with cirrhosis
Young presenting age9,32
(25%)
 Biochemical response rate in women <40 years old at diagnosis is less than 50%
AMA negative8,9,28
(5%-10%)
 Clinical course identical to AMA-positive PBC
Intractable pruritus12,17
(dynamic frequency reported)
 Consider referral for clinical trials specifically targeting pruritus
 Rarely can be severe enough to merit transplantation as the solitary indication
Overlap* with autoimmune hepatitis (AIH)14
(3%-20%; diagnostic criteria inconsistent)
 Severity of interface hepatitis predictive of biochemical nonresponse
- Unclear whether biochemical response criteria predict prognosis in overlap
 Inconclusive data regarding clinical outcome relative to PBC alone
B. PSC
Phenotypic Variant (% of Patient Population) Prognostic Implication
Young presenting age14
(frequency unclear—lack of consensus on disease
nomenclature between children and adult patients)
 Under 16 years more commonly present with an inflammatory phenotype
 Speculated to endure a more rapidly progressive course (unconfirmed)
Small duct disease13,62-64
(10%-15%)
 Less often symptomatic (30% vs. 53%; P < 0.01)
 Disease progression infrequent relative to classical PSC
- Transplantation rate 10%
- TFS relative to classical form: 29 vs. 17 years; P 5 0.04
 Increased risk of CCA not evident in small duct disease
 Up to 25% may progress to large duct disease over 7 years
Dominant strictures50,60
(12%-60%)
 Strictly defined on ERC criteria
 Increased mortality largely attributed to inability in differentiating
benign from malignant lesions
 Reduced TFS (particularly if coexists with colitis)
- 25% vs. 73% over 20 years; P 5 0.011
Coexisting Crohn’s disease75
(13%; one study)
 50% female
 22% have small duct PSC—consequently exhibit improved LT-free survival
 Impact of small intestinal vs. colonic Crohn’s not yet discerned
Elevated serum IgG4 levels46-49
(9%-15%)
 More significant elevations in serum liver biochemistry/Mayo score
 Impact on clinical outcome unclear
Overlap* with autoimmune hepatitis (AIH)14
(1%-53%; diagnostic criteria inconsistent)
 50% of children diagnosed with AIH age <16 years “evolve” into PSC
 Inconclusive data regarding clinical outcome relative to PSC alone
 Frequency of coexisting IBD similar (PSC likely dominant disease process)
*The prevalence of overlap is difficult to ascertain because of publication bias, variable definitions, and considerable heterogeneity between syndrome designa-
tions. Moreover, the limitations of applying surrogates of outcome to settings distinct from which they were originally intended must be recognized (covered else-
where14). Given small numbers of patients comprising few nonrandomized, nonblinded studies, evidenced-based risk-stratification centerd on the relative presence/
absence of overlap features is not possible currently and worthy of prospective multicenter collaborative investigation.
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single-center study wherein age<55 years conferred poorer
relative survival compared to matched controls (SMR,
7.4).29 Younger women often present with more pro-
nounced elevations in serum ALP17 but frequently fail ther-
apy owing to transaminase elevations,9 possibly reflecting a
more hepatitic phenotype. This is noteworthy given that
the degree of interface activity is recognized to influence
disease progression in PBC.10,14,30,31 The impact of pre-
senting age was less apparent in men,9 who, despite being
older at diagnosis, exhibited greater frequency of nonres-
ponse overall, possibly reflecting more advanced baseline
fibrosis at presentation.32
The strong influence of presenting age may allow more
timely stratification of at-risk groups (preceding assess-
ment of 12-month biochemical response), who, because
of a relatively poor predicted survival, would be poten-
tially eligible for early clinical trial entry. However, the
more opportune recognition of at-risk individuals must
ensure that low-risk patients are not over treated,27 partic-
ularly given that 50% of all patients under 50 do indeed
meet current biochemical response criteria on UDCA.9
Optimization of Criteria
Existing biochemical response criteria remain to be
refined, with a subgroup of responders still at risk of devel-
oping adverse events. There is evidence that reduction in
hepatic venoportal gradient whereas on UDCA treatment
associates with improved TFS in PBC, stratifying through
a 20% gradient decline over 2 years.3 Conversely, the pres-
ence of gastroesophageal varices (GEVs) is a poor prognos-
tic factor4; and given that PH can develop in the absence of
cirrhosis secondary to presinusoidal resistance, several algo-
rithms for prediction of GEVs are proposed. Although
advocated for guiding variceal surveillance, such models
carry preselection bias, given that study populations from
which they derive were included after endoscopy referral.
Moreover, no current strategy allows noninvasive discrimi-
nation of clinically significant PH.
With regard to patient survival, performance characteris-
tics of the aspartate aminotransferase (AST)/platelet ratio
index (APRI) have been ascertained given ability to infer
not only PH, but also fibrosis.3,28 When applied at baseline
or at 1 year, APRI was identified as an independent predic-
tor of TFS across a tertiary center population (n 5 386),
with a discriminatory cutpoint of 0.54 externally validated
in three international cohorts.28,33 Moreover, 1-year APRI
identified the subgroup at risk of disease progression and
earlier mortality despite successful attainment of biochemi-
cal response (Table 3C), indicating independent and addi-
tive prognostic information to existing criteria.28,34,35
Newer, highly complex, and robust computational algo-
rithms incorporating facets of APRI in addition to conven-
tional biochemical response parameters have recently been
Ta
bl
e
3
.C
on
tin
ue
d
C
.
O
pt
im
iz
at
io
n
of
P
re
vi
ou
s
R
es
po
ns
e
C
ri
te
ri
a
(2
0
1
3
-2
0
1
5
)
P
ro
po
se
d
R
es
po
ns
e
C
ri
te
ri
a
D
er
iv
at
io
n
C
oh
or
t;
N
o.
of
Pa
ti
en
ts
Fo
llo
w
-u
p
In
te
rv
al
(Y
ea
rs
)
Va
lid
at
io
n
S
er
ie
s;
N
o.
of
Pa
ti
en
ts
N
et
R
ec
la
ss
ifi
ca
ti
on
In
de
x
(N
R
I)
(%
)
B
io
ch
em
ic
al
re
sp
on
se
1
A
P
R
I-
r1
0
.5
4
*
2
8
n
5
3
5
2
;
si
ng
le
-c
en
te
r
M
ed
ia
n:
7
n
5
4
4
6
;
m
ul
tic
en
te
r
(I
)2
8
2
0
U
K
-P
B
C
ri
sk
sc
or
e†
3
4
Pr
og
no
st
ic
in
de
x
co
m
pr
is
in
g
bi
lir
ub
in
,
AL
P
ra
tio
,
AS
T,
AL
T
al
bu
m
in
,
an
d
pl
at
el
et
co
un
t
n
5
1
,9
1
6
;
m
ul
tic
en
te
r
(N
)
M
ed
ia
n:
7
n
5
1
,2
4
9
;
m
ul
tic
en
te
r
(N
)3
4
N
ot
sp
ec
ifi
ed
G
LO
B
E
sc
or
e;
w
w
w.
gl
ob
al
pb
c.
co
m
3
5
Pr
og
no
st
ic
in
de
x
co
m
pr
is
in
g
pa
tie
nt
ag
e,
bi
lir
ub
in
,
AL
P
ra
tio
,
al
bu
m
in
,
an
d
pl
at
el
et
co
un
t
n
5
2
,4
8
8
;
m
ul
tic
en
te
r
(I
)
M
ed
ia
n:
8
n
5
1
,6
3
1
;
m
ul
tic
en
te
r
(I
)3
5
2
5
-3
5
S
ev
er
al
re
sp
on
se
cr
ite
ria
ar
e
pr
op
os
ed
in
PB
C
,
w
he
re
in
LT
-f
re
e
su
rv
iv
al
ak
in
to
th
at
of
a
m
at
ch
ed
po
pu
la
tio
n
is
pr
ed
ic
te
d
af
te
r
at
ta
in
m
en
t
of
w
el
l-
de
fin
ed
pa
ra
m
et
er
s;
m
os
t
of
te
n
ap
pl
ie
d
at
1
-2
ye
ar
s
af
te
r
U
D
C
A
tr
ea
tm
en
t/
PB
C
di
ag
no
si
s.
Al
th
ou
gh
th
e
op
tim
um
cu
tp
oi
nt
fo
r
se
ru
m
AL
P
is
di
ffi
cu
lt
to
de
fin
e,
it
is
ap
pa
re
nt
th
at
ab
so
lu
te
le
ve
ls
du
rin
g
fo
llo
w
-u
p
pr
ed
ic
ts
ou
tc
om
e
w
ith
hi
gh
er
ac
cu
ra
cy
re
la
tiv
e
to
pe
rc
en
ta
ge
de
cr
ea
se
.
Ev
en
t
ra
te
s
in
re
sp
on
de
rs
(R
)
vs
.
no
nr
es
po
nd
er
s
(N
R
)
ar
e
pr
ov
id
ed
fo
r
pr
in
ci
pl
e
st
ud
ie
s
in
(A
).
M
od
ifi
ca
tio
ns
to
ex
is
tin
g
cr
ite
ria
;
sp
ec
ifi
ca
lly
,
ta
rg
et
in
g
pa
tie
nt
s
w
ith
ea
rly
-s
ta
ge
di
se
as
e,
as
w
el
l
as
6
-
vs
.
1
2
-m
on
th
bi
oc
he
m
i-
ca
l
re
sp
on
se
ha
ve
be
en
at
te
m
pt
ed
,
al
th
ou
gh
th
e
la
tt
er
ap
pr
oa
ch
is
aw
ai
tin
g
va
lid
at
io
n
(B
).
Im
pr
ov
em
en
ts
of
pr
ev
io
us
re
sp
on
se
cr
ite
ria
ar
e
be
in
g
at
te
m
pt
ed
,
w
ith
ex
am
pl
es
pr
ov
id
ed
fo
r
cu
rr
en
t
st
ud
ie
s
(C
).
S
in
gl
e-
an
d
m
ul
ti-
ce
nt
er
na
tio
na
l
(N
)
an
d
in
te
rn
at
io
na
l
(I
)
st
ud
ie
s
ar
e
de
no
te
d
ac
co
rd
in
gl
y.
*
Ap
pl
ic
at
io
n
of
AP
R
I
sc
or
e
at
1
ye
ar
(A
PR
I-
r1
)
to
al
l
pr
ee
xi
st
in
g
bi
oc
he
m
ic
al
cr
ite
ria
ha
s
be
en
sh
ow
n
to
im
pr
ov
e
pr
ed
ic
tiv
e
pe
rfo
rm
an
ce
.
†
En
dp
oi
nt
in
th
e
U
K-
PB
C
st
ud
y
w
as
tr
an
sp
la
nt
at
io
n,
or
liv
er
-r
el
at
ed
(a
s
op
po
se
to
al
l-
ca
us
e)
m
or
ta
lit
y.
Ab
br
ev
ia
tio
ns
:
AL
T,
al
an
in
e
am
in
ot
ra
ns
fe
ra
se
;
N
/A
,
no
t
ap
pl
ic
ab
le
;
PP
V,
po
si
tiv
e
pr
ed
ic
tiv
e
va
lu
e;
N
PV
,
ne
ga
tiv
e
pr
ed
ic
tiv
e
va
lu
e.
HEPATOLOGY, Vol. 00, No. 00, 2015 TRIVEDI ET AL. 7
published. These scoring systems derive from large, multi-
center cohorts as part of UK-PBC as well as the Global
PBC Study Group34,35 and convey probability of TFS on
a continuous, as opposed to dichotomous, scale (area
under the receiver operator curve [AUROC]: >0.9). In
addition to being internally validated, the latter in particu-
lar has been compared against a healthy age- and sex-
matched control population, demonstrating comparable
prognostic performance to Paris-I 1 APRI.35 However, it
remains uncertain above what point patients will be
deemed high risk enough for clinical trial stratification,
how the modifier effects of UDCA on risk score will influ-
ence outcome (delta change), and which additional strati-
fiers will continue to retain independent clinical impact.
Can Biochemical Surrogates Be
Extrapolated to PSC?
Serum bilirubin is inherent to many historic PSC prog-
nostic models, including the disease-specific Mayo score.36
Despite widespread application, the series from which the
latter derives antedates modern management of variceal
bleeding and receives further criticism given inability to
foreshadow adverse events (AEs) in previous clinical tri-
als.37 Although a persistently elevated bilirubin for >3
months incites concern for hepatobiliary malignancy,18
levels have a propensity to fluctuate with flares of cholangi-
tis and potentially influenced by biliary interventions.
There is no proven survival advantage, or reduction in
hepatobiliary/colorectal malignancy risk for PSC patients
receiving UDCA, and an increased predisposition toward
AEs well documented with high dosages (28-30 mg/kg/
day).1,5 Several groups have nevertheless attempted con-
struction of “ALP-based” biochemical response criteria
(Table 4),38-43 but ultimately, each has failed cross-
validation at the originally conceived time points. For
instance, the 1.53 the upper limit of normal (ULN) cut-
point proved discriminatory at 2 years in the Oxford
cohort (irrespective of UDCA receipt40), but was only
predictive when applied at 6 and 12 months in the Hei-
delberg and national UK series, respectively. Moreover, in
only one published study has the predictive value of ALP
as a continuous variable been confirmed before establish-
ing utility through dichotomization43; however, full statis-
tical methodology was not presented and clinical
endpoints incorrectly assessed as time-constrained events.
Systematic efforts to validate the prognostic utility of
serum ALP in PSC therefore remain in their infancy,
Table 4. Proposed ALP Thresholds in PSC
Proposed Criteria
(Attainment rate)
Derivation Cohort;
No. of Patients
Clinical Event Rate;
R vs. NR
(Interval) Endpoints Tested Apprehensions
Rochester*38
ALP normalization at any point
(median attainment time: 1 year)
(Achieved by 40% of patients)
n587; single-center 14% vs. 33%; P50.02
(median follow-up: 7.3 yrs)
Death, LT, CCA  Small number of patients
20% of UDCA-treated individuals
reached clinical endpoint despite
normal serum ALP
Oxford40
ALP <1.53 ULN at 2 years
(achieved by 40% of patients)
n5139; single-center 6% vs. 38%; P < 0.0001
(median follow-up 10 years)
Decompensation,
Death, LT, CCA
 Tested in Heidelberg study at
6 months39 and UK-PSC multicenter
study at 1-year time point41
 ALP threshold not successfully vali-
dated at original 2-year time point
Scandinavian multicenter42
ALP >40% decline from baseline
or normal at 1 year.
(achieved by 40% of patients)
n5195; multicenter (I) Rate not specified;
Difference between
groups: P < 0.001
Death, LT, CCA  Not successfully validated39
Heidelberg39
ALP <1.53 ULN, or
ALP 50% decline, or
ALP normal 6 months from baseline
(achieved by 51% of patients—any above)
n5185; single-center 13% vs. 49%; P < 0.05
(median follow-up: 10 years)
Death, LT, CCA  Clinical event rate not significantly
different between groups when ALP
<1.53 ULN threshold applied (in
isolation) at 1 year
UK-PSC†41
Criteria (1): ALP <1.53 ULN at 1 year
Criteria (2): ALP <2.03 ULN at 2 years
(attainment rates not yet available)
n51,200;
multicenter (N)
Rate not specified;
Significant difference
between groups:
(1) P < 0.001 and
(2) P50.015
LT only  Threshold of ALP <1.53 ULN did
not prove discriminatory when
applied at 2 years
Emerging biochemical response criteria in PSC patients based on varying thresholds of serum ALP applied 6-24 months after diagnosis. Attainment of these crite-
ria is purported to infer significantly improved clinical outcome in the individual cohorts studied, although comparisons to matched control population are yet to be
drawn, and none of the inclusive studies have assessed serum ALP as a continuous variable before application of presented cutpoints.
*Predefined time point not specified.
†Full results yet to be published.
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and none of the studies thus far incorporate a compara-
tor control group. Therefore, it is difficult to infer what
an improved serum ALP truly means, given that “PSC
biochemical responders” may still benefit from trials of
new therapy if survival significantly deviates from the
healthy population. Spontaneous normalization has
been reported in up to 40% of patients;38 and whereas
this may indicate a slowly progressive form of disease,
based on available evidence ALP cannot be recom-
mended as a stand-alone stratifier of risk in PSC.
Immunoserological Indices and Coexisting
Autoimmunity
PBC-Specific Anti-Nuclear Antibodies
Unlike AMA, which holds no prognostic value,8,9,28
there exist several anti-nuclear antibody (ANA) subtypes
that may associate with adverse clinical outcome in PBC.
Baseline anti-gp210 reactivity imparts over a 6-fold risk
of progression to liver failure/transplantation44 and
although neither independent nor additive to biochemical
Table 5. Prognosis-Related Histological Themes in PBC
Feature Comments
Fibrosis  Advanced septal fibrosis predictive of UDCA failure and clinical outcome10,25,68
Interface hepatitis  Positive correlation with AST/ALT (Spearman’s q: 0.469/0.395; P < 0.05)66
 Moderate-severe activity* independently predictive of biochemical nonresponse, histological stage progression,
progression to transplantation, and death (relative risk: 1.9; P 5 0.002)10,30,31,72
 Improvement in interface activity (in the absence of significant fibrosis) with corticosteroids reported in at least two randomized
trials and one multicenter observational study77
Ductopenia  Negative correlation of bile duct ratio† with serum ALP (Spearman’s q: 20.362; P < 0.05)66
 Duct loss in >50% of portal tracts predicts histological disease progression and failure to meet biochemical response25
 Premature ductopenic variant affects 5%-10% of patients: characterized by: rapid-onset bile duct loss without significant
baseline fibrosis, severe icteric cholestasis, and rapid progression toward cirrhosis (<5 years67)
Chronic cholestasis  Deposition of orcein-positive granules in periportal hepatocytes predictive of development of cirrhosis-related conditions65
*Moderate: segmental necrosis at periphery of >50% of portal tracts or circumferential necrosis in <50% of portal tracts; severe: circumferential necrosis in
>50% of portal tracts.
†Ratio of the number of portal tracts with ducts to total number of portal tracts.
Table 6. Noninvasive Evaluation of Liver Fibrosis
Modality PBC PSC
VCTE Precedents:
 Increased risk of clinical events (decompensation, LT, and liver-
related mortality) independent of biochemical response in patients
with LSM >9.6 kPa, or DLSM >2.1 kPa/yr70
Precedents:
 Higher baseline LSM (>9.9kPa most sensitive), or DLSM>1.3kPa/yr.
predictive of adverse clinical events.72 Low-risk group best discrimi-
nated by LSM 6.5kPa
Studied cohorts:
 n 5 150; single-center and UDCA treated
Studied cohorts:
 n 5 167; single-center
Comment:
 Proven surrogate of fibrosis in PBC. However, validation as an out-
come predictor pending
Comment:
 Impact of severe cholestasis/cholangitis/IBD activity uncertain
 Validation as an outcome predictor pending
 Unclear whether adds predictive value to biochemical response
status
ELF Precedents:
 Significant differences in clinical event rate between score tertiles73
 D1-point increase imparts 3-fold greater risk of liver-related events
Precedents:
 LT-free survival significantly greater in patients harboring low
(9.7 years) vs. high (1.3 years) ELF scores (threshold, 10.6)74
Studied cohorts:
 n 5 161; multicenter national data extrapolated from a clinical trial
of methotrexate and UDCA
Studied cohorts:
 n 5 167 (derivation) 1 138 (validation)
Comment:
 Unclear whether adds predictive value to biochemical response
status
Comment:
 Internal multicenter validation. However, short disease duration in LT-
free survivors in the original report (<5 years)
 Impact of longitudinal stability vs. fluctuations over time yet to be
determined
 Not yet validated
 Impact of longitudinal stability vs. fluctuations over time yet to be
determined
 Unclear whether stratifier of disease severity vs. stage
 Unclear whether stratifier of disease severity vs. stage
Abbreviation: kPa/yr, kilopascals per year.
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Fig. 2B. Proposed pathway to clinical trial recruitment in PSC. The unpredictable clinical nature and dearth of effective medical therapy in
PSC means that the vast majority of patients (outside of transplant criteria) currently harbor >1 high-risk classifier at time of presentation (A),
including the presence of colitis, persistently elevated liver biochemistry, or features predictive of advancing fibrosis or future cholangiographic
progression. Symptomatic presentations, in addition to indicators of advancing fibrosis, also predict adverse clinical outcome, although the rela-
tive and independent predictive value between modalities are yet to be established in PSC, with ELF score being somewhat restricted and of lim-
ited routine availability. Moreover, as a continuous variable, the optimum stratification threshold utilizing elastography is not yet defined, with
LSM >9.9 kPa the best discriminator for identifying high-risk individuals, yet 6.5 kPa most indicative of early disease. Nevertheless, the
dynamic impact of chronal increments is well demonstrated for elastography (B) and possibly for progressive MRC scores (not illustrated; formal
publication pending); signifying further groups in whom clinical trials should be encouraged. Conversely, asymptomatic patients with small duct
disease, as well as those with classical PSC achieving persistently low/normal liver biochemistry who maintain stable fibrotic indices in the
absence of cholangiographic progression, likely herald a more consistent low-risk profile (C), albeit with need for longitudinal appraisal (D) given
that early predictive models of disease progression are not yet available. Indeed, regular risk assessment of malignant complications is critical to
ensure long-term patient safety, given that no early or robust predictors of future CCA currently exist. To this effect, a position for even those in
the lower-risk category (with large duct disease) to be considered for clinical trials specifically targeted at reducing CCA incidence can also be
argued (open arrows), while accepting the strong probability that other PSC-related clinical events develop at a low incidence. The optimum fre-
quency of routine radiological surveillance is often debated (E), with no evidence-based guidance in this regard. A suggested policy of 12-
monthly (detection of gallbladder polyps), or 6-monthly in patients with cirrhosis (HCC surveillance) is proposed in keeping with current guide-
lines. Abbreviations: F/Up, follow-up; HPB, hepatopancreatobiliary; kPa, kilopascals.
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response12,30 may assist in the earlier, prospective identifi-
cation of high-risk patients.27,44 Anti-centromere anti-
bodies similarly associate with PH,44 although more often
present in autoimmune connective tissue disease. Extrahe-
patic autoimmunity develops in 60% of PBC patients;
however, impact on liver-related outcomes is not readily
apparent.45
Serum Immunoglobulin G Subclass 4 in PSC
Between 9% and 15% of PSC patients have raised
serum immunoglobulin subclass 4 (IgG4) values,46-49 and
at least three separate studies support clinical distinctions
based on elevations; those having higher than normal val-
ues (>1.4 g/L) exhibiting greater derangements in liver
biochemistry.46-48 One group identified shorter median
time to transplantation in patients harboring elevated
serum IgG4,48 although this observation has repeatedly
failed replication across several international centers.49
Therefore, the stratifying properties of serum IgG4 in
PSC remain unsubstantiated and require further
evaluation.
Impact of Colitis in PSC
Several historic studies suggest that the presence of coli-
tis influences liver disease progression. However, many
were flawed given their assessment of IBD as a time-fixed
covariate; and the chronological displacement of disease
presence and activity between gut and liver manifestations
impart significant difficulties in examining colitis as a risk
stratifier. Nevertheless, in a prospective follow-up of nearly
200 PSC patients, all hepatobiliary malignancies were
observed to develop on a background of concurrent colitis,
with no cancers in the absence of IBD.50 Moreover, TFS
independent of CCA was also significantly different
between groups (23% vs. 80%; P 5 0.045). The negative
prognostic impact of colitis on liver-related outcomes has
since been confirmed in a large Dutch PSC cohort (n 5
161) as well as two population-based series.13,51-53
Cholangiographic Stratification in PSC
Several cholangiographic prognostic models derived
from endoscopic retrograde cholangiographic (ERC)
appearances have been proposed54; however, diagnostic
paradigms have evolved and no correlation between
severity of ductal involvement and survival through
two-dimensional magnetic resonance cholangiography
(MRC) was demonstrated. Nevertheless, a promising
study utilizing annual three-dimensional MRC to score
liver parenchymal appearances, PH and bile duct lesions
predicted radiological progression from baseline with
high accuracy (AUROC, >0.8).55 Sixty percent of
patients developed evolving changes over 4 years, and
preliminary data indicate baseline radiological score to
be a highly sensitive prognosticator of clinical outcome,
with the most predictive components relating to paren-
chymal as opposed to ductal changes.56
Dominant Strictures
Dominant strictures (DS) were originally defined
based on historical ERC findings, and consensus opin-
ion as to how such lesions are to be classified noninva-
sively is yet to be delivered. Observational studies report
a presenting frequency of 12%-60%,57,58 with no
population-level indications of true incidence. Natural
history data are similarly restricted to specialist centers,
with reduced survival largely reflecting difficulties in
CCA recognition.18,50,58,59 However, more recent
reports suggest actuarial TFS as significantly poorer irre-
spective of cancer development and heavily influenced
by presence of colitis.50,60 Several investigators report
biochemical and clinical improvements after endoscopic
therapy,61 but the prognostic impact of intervention
needs assessment.
Small Duct PSC
Small duct PSC (sdPSC) represents 10%-15% of the
disease spectrum, with affected individuals less often
symptomatic.62 There is now well-validated evidence
that disease progression is relatively infrequent, occur-
ring over a longer time period than the classical
form.13,63,64 Although colitis manifests to a similar
degree there is little to suggest an impact on liver-related
outcomes; and given that survival patterns mirror those
of an age- and sex-matched population, the need for
investigative therapy is perhaps less perceptible in those
with the small duct variant.
Histological Stage and Noninvasive
Evaluation
Disease identification in PBC and PSC is largely reli-
ant on serology and cholangiography, respectively, in the
appropriate clinical and biochemical context. Neverthe-
less, liver biopsy is invaluable in cases of diagnostic
doubt and provides key information with regard to dis-
ease activity and severity that may improve predictive
power of existing algorithms.31
Several contemporary histological systems have
emerged for PBC,65,66 with the aim of accurately repre-
senting interface activity, ductopenia, chronic cholesta-
sis, and fibrotic indices—variables well known to
forecast biochemical nonresponse and clinical outcome
(Table 5).9,10,14,25,30,31,67,68 Common histological
changes in PSC include interface activity, ductopenia
and concentric periductal fibrosis, although individual
prognostic weightings are unclear, and no disease-
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specific classification exists. Nevertheless, data extrapo-
lated from the Dutch population-based registry (n 5
64) indicate that scoring through PBC-based classifica-
tion systems, as well as lobular fibrosis stage (Ishak), sig-
nificantly associates with time to transplantation in PSC
patients.69
Histology remains the gold standard for assessing
fibrosis progression—a clear determinant of clinical out-
come. However, the intrusiveness, coupled with well-
known sampling variability and disconcordant reporting
in cholestatic disease, has fostered development of sev-
eral noninvasive surrogates (Table 6). In the current
clinical climate, histological stratification holds limited
routine applicability, although staging systems and eval-
uation of prognosis-related histological lesions may have
a place as surrogate endpoints in clinical trials—a topic
beyond the scope of this review.
Vibration Controlled Transient Elastography
The accuracy of vibration controlled transient elastog-
raphy (VCTE) in fibrosis staging has been demonstrated
in at least two large PBC cohorts,70,71 with prognostic
capabilities independent of biochemical response evi-
dent in a recent single-center retrospective study of 150
patients.70 Though VCTE outperforms APRI as well as
several noninvasive surrogates of fibrosis, it remains
unclear whether the former confers additive discrimina-
tion to biochemical response. The prognostic impact of
liver stiffness measurement (LSM) in PSC has also
recently been described,72 and as with previous descrip-
tors, correlated well with degree of liver fibrosis but per-
forming best at extremes of histological stage (F1 and
F3). More striking was the observation that increased
baseline measurements and rate of change in LSM were
strongly and independently linked with PSC-specific
clinical events.72
LSM, in addition to reflecting severity of fibrosis, can
also be influenced by extrahepatic cholestasis and may
not necessarily capture disease facets, such as hepatic
necroinflammatory activity, ductopenia and PH. Never-
theless, encouraging data from existing series strongly
support VCTE-derived LSM—absolute values as well as
fluctuations over time—as major predictors of AEs.
Given correlations with mortality and liver transplanta-
tion (LT) in PBC and PSC, VCTE may represent a
generic surrogate in chronic cholestatic liver disease, and
prospective validations as part of multicenter collabora-
tive efforts continue to emerge.
Enhanced Liver Fibrosis Score
The enhanced liver fibrosis (ELF) score bears similar
prognostic utility to histological fibrosis staging in
PBC,73 although akin to VCTE, additive predictive
value to biochemical response has not been demon-
strated. More recent focus on the stratifying properties
in PSC led to a notable publication by the Norwegian
Study Group. Therein, patients exhibited significantly
divergent TFS curves according to tertile distribution,
or through a dichotomous Youden-index-derived cut-
point.74 Moreover, ELF score correlated well with elas-
tography and provided incremental prognostic utility to
Mayo risk. However, one caveat is the relatively short
disease duration experienced by transplant-free survivors
(median, 0.2 years) and of further uncertainty is how
dynamic fluctuations impact outcome longitudinally.
Nevertheless, this study represents the first noninvasive,
externally validated serum biomarker panel in PSC.
Clinical Integration and Prospective
Outlook
Biochemical nonresponders represent the most read-
ily identifiable at-risk group in PBC, and incorporating
a step-wise algorithm with response criteria as the cen-
tral feature is likely to capture the greatest breadth of
individuals who will benefit from clinical trials (Fig.
2A). Validation at interim time points for groups who
commonly experience treatment failure is urgently
decreed and may assist in the earlier identification of
high-risk patients. Along similar lines, prospective bank-
ing of biological materials with paired long-term clinical
follow-up data could yield predictive markers from the
point of diagnosis through interrogation of key path-
ways underlying nonresponse. The few PBC patients
who endure AEs despite attainment of response remain
poorly defined, but increasingly recognized28,35; and the
additional impact of “biochemical escape”—wherein
previous responders develop subsequent elevations in
laboratory parameters—yet to be explored. The additive
predictive value of histology and its noninvasive surro-
gates to existing criteria also requires further validation
in a manner similar to that presented for APRI, in addi-
tion to newer biochemical response criteria with
dynamic predictive capabilities.31,34,35
By contrast, safe discrimination of risk phenotypes in
PSC is not possible through early application of a single
modality, and timely assessment requires harnessing
multiple predictive techniques collectively (Fig. 2B).
Despite invasiveness of histological stratification, the
advent of VCTE and related biomarkers hold promise,
although predictive performance is best at stages of
advanced fibrosis implying surrogacy toward disease
stage, rather than severity, and prospective validation
currently remaining. Present biochemical surrogates are
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far from robust, and it is crucial for future endeavors to
secure appropriate control groups before stratifying PSC
patients as low risk based on serum ALP alone, particu-
larly given that 20% of UDCA-treated patients with
normal laboratory values still develop progressive dis-
ease.38 Further efforts are also needed to appraise the rel-
ative independence of existing parameters that stratify
risk, both consequentially and concurrently.
Conclusion
Patients with PBC and PSC remain a heterogeneous
cohort with concerns surrounding reliable outcome
forecasting. Stratification paradigms are shifting with
increased efforts toward recognition of at-risk pheno-
types. The increased utilization of such tools, both clini-
cally and in trial settings, is hoped to allow for more
personalized care. In so doing, low-risk patients can be
reassured and managed accordingly, whereas higher-risk
individuals are offered tailored care, as well as access to
carefully designed trials relevant to their disease course.
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